Pluripotent stem cell generated directly from a somatic cell
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from a somatic cell. The iPSC technology was pioneered by Shinya Yamanaka's lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes (named Myc, Oct3/4, Sox2 and Klf4), collectively known as Yamanaka factors, encoding transcription factors could convert somatic cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent."
Pluripotent stem cells hold promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
The most well-known type of pluripotent stem cell is the embryonic stem cell. However, since the generation of embryonic stem cells involves destruction (or at least manipulation) of the pre-implantation stage embryo, there has been much controversy surrounding their use. Patient-matched embryonic stem cell lines can now be derived using somatic cell nuclear transfer (SCNT).
Since iPSCs can be derived directly from adult tissues, they not only bypass the need for embryos, but can be made in a patient-matched manner, which means that each individual could have their own pluripotent stem cell line. These unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection. While the iPSC technology has not yet advanced to a stage where therapeutic transplants have been deemed safe, iPSCs are readily being used in personalized drug discovery efforts and understanding the patient-specific basis of disease.
Yamanaka named iPSCs with a lower case "i" due to the popularity of the iPod and other products.[dubious discuss]
In his Nobel seminar, Yamanaka cited the earlier seminal work of Harold Weintraub on the role of myoblast determination protein 1 (MyoD) in reprogramming cell fate to a muscle lineage as an important precursor to the discovery of iPSCs.
iPSCs are typically derived by introducing products of specific sets of pluripotency-associated genes, or "reprogramming factors", into a given cell type. The original set of reprogramming factors (also dubbed Yamanaka factors) are the transcription factors Oct4 (Pou5f1), Sox2, Klf4 and cMyc. While this combination is most conventional in producing iPSCs, each of the factors can be functionally replaced by related transcription factors, miRNAs, small molecules, or even non-related genes such as lineage specifiers.It is also clear that pro-mitotic factors such as C-MYC/L-MYC or repression of cell cycle checkpoints, such as p53, are conduits to creating a compliant cellular state for iPSC reprograming .
iPSC derivation is typically a slow and inefficient process, taking 12 weeks for mouse cells and 34 weeks for human cells, with efficiencies around 0.010.1%. However, considerable advances have been made in improving the efficiency and the time it takes to obtain iPSCs. Upon introduction of reprogramming factors, cells begin to form colonies that resemble pluripotent stem cells, which can be isolated based on their morphology, conditions that select for their growth, or through expression of surface markers or reporter genes.
Induced pluripotent stem cells were first generated by Shinya Yamanaka's team at Kyoto University, Japan, in 2006. They hypothesized that genes important to embryonic stem cell (ESC) function might be able to induce an embryonic state in adult cells. They chose twenty-four genes previously identified as important in ESCs and used retroviruses to deliver these genes to mouse fibroblasts. The fibroblasts were engineered so that any cells reactivating the ESC-specific gene, Fbx15, could be isolated using antibiotic selection.
Upon delivery of all twenty-four factors, ESC-like colonies emerged that reactivated the Fbx15 reporter and could propagate indefinitely. To identify the genes necessary for reprogramming, the researchers removed one factor at a time from the pool of twenty-four. By this process, they identified four factors, Oct4, Sox2, cMyc, and Klf4, which were each necessary and together sufficient to generate ESC-like colonies under selection for reactivation of Fbx15.
In June 2007, three separate research groups, including that of Yamanaka's, a Harvard/University of California, Los Angeles collaboration, and a group at MIT, published studies that substantially improved on the reprogramming approach, giving rise to iPSCs that were indistinguishable from ESCs. Unlike the first generation of iPSCs, these second generation iPSCs produced viable chimeric mice and contributed to the mouse germline, thereby achieving the 'gold standard' for pluripotent stem cells.
These second-generation iPSCs were derived from mouse fibroblasts by retroviral-mediated expression of the same four transcription factors (Oct4, Sox2, cMyc, Klf4). However, instead of using Fbx15 to select for pluripotent cells, the researchers used Nanog, a gene that is functionally important in ESCs. By using this different strategy, the researchers created iPSCs that were functionally identical to ESCs.
Reprogramming of human cells to iPSCs was reported in November 2007 by two independent research groups: Shinya Yamanaka of Kyoto University, Japan, who pioneered the original iPSC method, and James Thomson of University of Wisconsin-Madison who was the first to derive human embryonic stem cells. With the same principle used in mouse reprogramming, Yamanaka's group successfully transformed human fibroblasts into iPSCs with the same four pivotal genes, Oct4, Sox2, Klf4, and cMyc, using a retroviral system, while Thomson and colleagues used a different set of factors, Oct4, Sox2, Nanog, and Lin28, using a lentiviral system.
Obtaining fibroblasts to produce iPSCs involves a skin biopsy, and there has been a push towards identifying cell types that are more easily accessible. In 2008, iPSCs were derived from human keratinocytes, which could be obtained from a single hair pluck. In 2010, iPSCs were derived from peripheral blood cells, and in 2012, iPSCs were made from renal epithelial cells in the urine.
Other considerations for starting cell type include mutational load (for example, skin cells may harbor more mutations due to UV exposure), time it takes to expand the population of starting cells, and the ability to differentiate into a given cell type.
The generation of induced pluripotent cells is crucially dependent on the transcription factors used for the induction.
Oct-3/4 and certain products of the Sox gene family (Sox1, Sox2, Sox3, and Sox15) have been identified as crucial transcriptional regulators involved in the induction process whose absence makes induction impossible. Additional genes, however, including certain members of the Klf family (Klf1, Klf2, Klf4, and Klf5), the Myc family (c-myc, L-myc, and N-myc), Nanog, and LIN28, have been identified to increase the induction efficiency.
Although the methods pioneered by Yamanaka and others have demonstrated that adult cells can be reprogrammed to iPS cells, there are still challenges associated with this technology:
The table on the right summarizes the key strategies and techniques used to develop iPS cells in the first five years after Yamanaka et al.'s 2006 breakthrough. Rows of similar colors represent studies that used similar strategies for reprogramming.
One of the main strategies for avoiding problems (1) and (2) has been to use small molecules that can mimic the effects of transcription factors. These compounds can compensate for a reprogramming factor that does not effectively target the genome or fails at reprogramming for another reason; thus they raise reprogramming efficiency. They also avoid the problem of genomic integration, which in some cases contributes to tumor genesis. Key studies using such strategy were conducted in 2008. Melton et al. studied the effects of histone deacetylase (HDAC) inhibitor valproic acid. They found that it increased reprogramming efficiency 100-fold (compared to Yamanaka's traditional transcription factor method). The researchers proposed that this compound was mimicking the signaling that is usually caused by the transcription factor c-Myc. A similar type of compensation mechanism was proposed to mimic the effects of Sox2. In 2008, Ding et al. used the inhibition of histone methyl transferase (HMT) with BIX-01294 in combination with the activation of calcium channels in the plasma membrane in order to increase reprogramming efficiency. Deng et al. of Beijing University reported in July 2013 that induced pluripotent stem cells can be created without any genetic modification. They used a cocktail of seven small-molecule compounds including DZNep to induce the mouse somatic cells into stem cells which they called CiPS cells with the efficiency at 0.2% comparable to those using standard iPSC production techniques. The CiPS cells were introduced into developing mouse embryos and were found to contribute to all major cells types, proving its pluripotency.
Ding et al. demonstrated an alternative to transcription factor reprogramming through the use of drug-like chemicals. By studying the MET (mesenchymal-epithelial transition) process in which fibroblasts are pushed to a stem-cell like state, Ding's group identified two chemicals ALK5 inhibitor SB431412 and MEK (mitogen-activated protein kinase) inhibitor PD0325901 which was found to increase the efficiency of the classical genetic method by 100 fold. Adding a third compound known to be involved in the cell survival pathway, Thiazovivin further increases the efficiency by 200 fold. Using the combination of these three compounds also decreased the reprogramming process of the human fibroblasts from four weeks to two weeks.
In April 2009, it was demonstrated that generation of iPS cells is possible without any genetic alteration of the adult cell: a repeated treatment of the cells with certain proteins channeled into the cells via poly-arginine anchors was sufficient to induce pluripotency. The acronym given for those iPSCs is piPSCs (protein-induced pluripotent stem cells).
Another key strategy for avoiding problems such as tumorgenesis and low throughput has been to use alternate forms of vectors: adenovirus, plasmids, and naked DNA or protein compounds.
In 2008, Hochedlinger et al. used an adenovirus to transport the requisite four transcription factors into the DNA of skin and liver cells of mice, resulting in cells identical to ESCs. The adenovirus is unique from other vectors like viruses and retroviruses because it does not incorporate any of its own genes into the targeted host and avoids the potential for insertional mutagenesis. In 2009, Freed et al. demonstrated successful reprogramming of human fibroblasts to iPS cells. Another advantage of using adenoviruses is that they only need to present for a brief amount of time in order for effective reprogramming to take place.
Also in 2008, Yamanaka et al. found that they could transfer the four necessary genes with a plasmid. The Yamanaka group successfully reprogrammed mouse cells by transfection with two plasmid constructs carrying the reprogramming factors; the first plasmid expressed c-Myc, while the second expressed the other three factors (Oct4, Klf4, and Sox2). Although the plasmid methods avoid viruses, they still require cancer-promoting genes to accomplish reprogramming. The other main issue with these methods is that they tend to be much less efficient compared to retroviral methods. Furthermore, transfected plasmids have been shown to integrate into the host genome and therefore they still pose the risk of insertional mutagenesis. Because non-retroviral approaches have demonstrated such low efficiency levels, researchers have attempted to effectively rescue the technique with what is known as the PiggyBac Transposon System. Several studies have demonstrated that this system can effectively deliver the key reprogramming factors without leaving footprint mutations in the host cell genome. The PiggyBac Transposon System involves the re-excision of exogenous genes, which eliminates the issue of insertional mutagenesis.
In January 2014, two articles were published claiming that a type of pluripotent stem cell can be generated by subjecting the cells to certain types of stress (bacterial toxin, a low pH of 5.7, or physical squeezing); the resulting cells were called STAP cells, for stimulus-triggered acquisition of pluripotency.
In light of difficulties that other labs had replicating the results of the surprising study, in March 2014, one of the co-authors has called for the articles to be retracted. On 4 June 2014, the lead author, Obokata agreed to retract both the papers  after she was found to have committed 'research misconduct' as concluded in an investigation by RIKEN on 1 April 2014.
MicroRNAs are short RNA molecules that bind to complementary sequences on messenger RNA and block expression of a gene. Measuring variations in microRNA expression in iPS cells can be used to predict their differentiation potential. Addition of microRNAs can also be used to enhance iPS potential. Several mechanisms have been proposed. ES cell-specific microRNA molecules (such as miR-291, miR-294 and miR-295) enhance the efficiency of induced pluripotency by acting downstream of c-Myc. microRNAs can also block expression of repressors of Yamanaka's four transcription factors, and there may be additional mechanisms induce reprogramming even in the absence of added exogenous transcription factors.
Induced pluripotent stem cells are similar to natural pluripotent stem cells, such as embryonic stem cells, in many aspects, such as the expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling time, embryoid body formation, teratoma formation, viable chimera formation, and potency and differentiability, but the full extent of their relation to natural pluripotent stem cells is still being assessed.
Gene expression and genome-wide H3K4me3 and H3K27me3 were found to be extremely similar between ES and iPS cells. The generated iPSCs were remarkably similar to naturally isolated pluripotent stem cells (such as mouse and human embryonic stem cells, mESCs and hESCs, respectively) in the following respects, thus confirming the identity, authenticity, and pluripotency of iPSCs to naturally isolated pluripotent stem cells:
Recent achievements and future tasks for safe iPSC-based cell therapy are collected in the review of Okano et al.
The task of producing iPS cells continues to be challenging due to the six problems mentioned above. A key tradeoff to overcome is that between efficiency and genomic integration. Most methods that do not rely on the integration of transgenes are inefficient, while those that do rely on the integration of transgenes face the problems of incomplete reprogramming and tumor genesis, although a vast number of techniques and methods have been attempted. Another large set of strategies is to perform a proteomic characterization of iPS cells. Further studies and new strategies should generate optimal solutions to the five main challenges. One approach might attempt to combine the positive attributes of these strategies into an ultimately effective technique for reprogramming cells to iPS cells.
Another approach is the use of iPS cells derived from patients to identify therapeutic drugs able to rescue a phenotype. For instance, iPS cell lines derived from patients affected by ectodermal dysplasia syndrome (EEC), in which the p63 gene is mutated, display abnormal epithelial commitment that could be partially rescued by a small compound.
An attractive feature of human iPS cells is the ability to derive them from adult patients to study the cellular basis of human disease. Since iPS cells are self-renewing and pluripotent, they represent a theoretically unlimited source of patient-derived cells which can be turned into any type of cell in the body. This is particularly important because many other types of human cells derived from patients tend to stop growing after a few passages in laboratory culture. iPS cells have been generated for a wide variety of human genetic diseases, including common disorders such as Down syndrome and polycystic kidney disease. In many instances, the patient-derived iPS cells exhibit cellular defects not observed in iPS cells from healthy subjects, providing insight into the pathophysiology of the disease. An international collaborated project, StemBANCC, was formed in 2012 to build a collection of iPS cell lines for drug screening for a variety of disease. Managed by the University of Oxford, the effort pooled funds and resources from 10 pharmaceutical companies and 23 universities. The goal is to generate a library of 1,500 iPS cell lines which will be used in early drug testing by providing a simulated human disease environment. Furthermore, combining hiPSC technology and small molecule or genetically encoded voltage and calcium indicators provided a large-scale and high-throughput platform for cardiovascular drug safety screening.
A proof-of-concept of using induced pluripotent stem cells (iPSCs) to generate human organ for transplantation was reported by researchers from Japan. Human 'liver buds' (iPSC-LBs) were grown from a mixture of three different kinds of stem cells: hepatocytes (for liver function) coaxed from iPSCs; endothelial stem cells (to form lining of blood vessels) from umbilical cord blood; and mesenchymal stem cells (to form connective tissue). This new approach allows different cell types to self-organize into a complex organ, mimicking the process in fetal development. After growing in vitro for a few days, the liver buds were transplanted into mice where the 'liver' quickly connected with the host blood vessels and continued to grow. Most importantly, it performed regular liver functions including metabolizing drugs and producing liver-specific proteins. Further studies will monitor the longevity of the transplanted organ in the host body (ability to integrate or avoid rejection) and whether it will transform into tumors. Using this method, cells from one mouse could be used to test 1,000 drug compounds to treat liver disease, and reduce animal use by up to 50,000.
In 2021, a switchable Yamanaka factors-reprogramming-based approach for regeneration of damaged heart without tumor-formation was demonstrated in mice and was successful if the intervention was carried out immediately before or after a heart attack.
Embryonic cord-blood cells were induced into pluripotent stem cells using plasmid DNA. Using cell surface endothelial/pericytic markers CD31 and CD146, researchers identified 'vascular progenitor', the high-quality, multipotent vascular stem cells. After the iPS cells were injected directly into the vitreous of the damaged retina of mice, the stem cells engrafted into the retina, grew and repaired the vascular vessels.
Labelled iPSCs-derived NSCs injected into laboratory animals with brain lesions were shown to migrate to the lesions and some motor function improvement was observed.
Beating cardiac muscle cells, iPSC-derived cardiomyocytes, can be mass-produced using chemically defined differentiation protocols. These protocols typically modulate the same developmental signaling pathways required for heart development . These iPSC-cardiomyocytes can recapitulate genetic arrhythmias and cardiac drug responses, since they exhibit the same genetic background as the patient from which they were derived.
In June 2014, Takara Bio received technology transfer from iHeart Japan, a venture company from Kyoto University's iPS Cell Research Institute, to make it possible to exclusively use technologies and patents that induce differentiation of iPS cells into cardiomyocytes in Asia. The company announced the idea of selling cardiomyocytes to pharmaceutical companies and universities to help develop new drugs for heart disease.
On March 9, 2018, the Specified Regenerative Medicine Committee of Osaka University officially approved the world's first clinical research plan to transplant a "myocardial sheet" made from iPS cells into the heart of patients with severe heart failure. Osaka University announced that it had filed an application with the Ministry of Health, Labor and Welfare on the same day.
On May 16, 2018, the clinical research plan was approved by the Ministry of Health, Labor and Welfare's expert group with a condition.
In October 2019, a group at Okayama University developed a model of ischemic heart disease using cardiomyocytes differentiated from iPS cells.
Although a pint of donated blood contains about two trillion red blood cells and over 107 million blood donations are collected globally, there is still a critical need for blood for transfusion. In 2014, type O red blood cells were synthesized at the Scottish National Blood Transfusion Service from iPSC. The cells were induced to become a mesoderm and then blood cells and then red blood cells. The final step was to make them eject their nuclei and mature properly. Type O can be transfused into all patients. Human clinical trials were not expected to begin before 2016.
The first human clinical trial using autologous iPSCs was approved by the Japan Ministry Health and was to be conducted in 2014 at the Riken Center for Developmental Biology in Kobe. However the trial was suspended after Japan's new regenerative medicine laws came into effect in November 2015. More specifically, an existing set of guidelines was strengthened to have the force of law (previously mere recommendations). iPSCs derived from skin cells from six patients with wet age-related macular degeneration were reprogrammed to differentiate into retinal pigment epithelial (RPE) cells. The cell sheet would be transplanted into the affected retina where the degenerated RPE tissue was excised. Safety and vision restoration monitoring were to last one to three years.
In March 2017, a team led by Masayo Takahashi completed the first successful transplant of iPS-derived retinal cells from a donor into the eye of a person with advanced macular degeneration. However it was reported that they are now having complications. The benefits of using autologous iPSCs are that there is theoretically no risk of rejection and that it eliminates the need to use embryonic stem cells. However, these iPSCs were derived from another person.
New clinical trials involving iPSCs are now ongoing not only in Japan, but also in the US and Europe. Research in 2021 on the trial registry Clinicaltrials.gov identified 129 trial listings mentioning iPSCs, but most were non-interventional.
To make iPSC-based regenerative medicine technologies available to more patients, it is necessary to create universal iPSCs that can be transplanted independently of haplotypes of HLA. The current strategy for the creation of universal iPSCs has two main goals: to remove HLA expression and to prevent NK cells attacks due to deletion of HLA. Deletion of the B2M and CIITA genes using the CRISPR/Cas9 system has been reported to suppress the expression of HLA class I and class II, respectively. To avoid NK cell attacks. transduction of ligands inhibiting NK-cells, such as HLA-E and CD47 has been used. HLA-C is left unchanged, since the 12 common HLA-C alleles are enough to cover 95% of the world's population.
A multipotent mesenchymal stem cell, when induced into pluripotence, holds great promise to slow or reverse aging phenotypes. Such anti-aging properties were demonstrated in early clinical trials in 2017. In 2020, Stanford University researchers concluded after studying elderly mice that old human cells when subjected to the Yamanaka factors, might rejuvenate and become nearly indistinguishable from their younger counterparts.
Induced pluripotent stem cell - Wikipedia
- Stem-cell therapy - Wikipedia - December 30th, 2022 [December 30th, 2022]
- Stem Cell Transplantation: What it Is, Process & Procedure - December 30th, 2022 [December 30th, 2022]
- Stem Cell Therapy for Arthritis | Arthritis-health - December 30th, 2022 [December 30th, 2022]
- FDA Warns About Stem Cell Therapies | FDA - U.S. Food and Drug ... - December 30th, 2022 [December 30th, 2022]
- Stem cell - Wikipedia - November 28th, 2022 [November 28th, 2022]
- Types of Stem Cell and Bone Marrow Transplants - American Cancer Society - November 28th, 2022 [November 28th, 2022]
- Novel stem cell therapy for repair of knee cartilage - Mayo Clinic - November 28th, 2022 [November 28th, 2022]
- Celebrities Are Officially Being Sued by FTX Retail Investors - November 20th, 2022 [November 20th, 2022]
- FDA Gives First Go Ahead for Lab Grown Meat Product - November 20th, 2022 [November 20th, 2022]
- Sam Bankman-Fried Admits the "Ethics Stuff" Was "Mostly a Front" - November 20th, 2022 [November 20th, 2022]
- "Elon" Plummets in Popularity as a Baby Name for Some Reason - November 20th, 2022 [November 20th, 2022]
- Celebrities' Bored Apes Are Hilariously Worthless Now - November 20th, 2022 [November 20th, 2022]
- Startup Says It's Building a Giant CO2 Battery in the United States - November 20th, 2022 [November 20th, 2022]
- Panicked Elon Musk Reportedly Begging Engineers Not to Leave - November 20th, 2022 [November 20th, 2022]
- Former Facebook Exec Says Zuckerberg Has Surrounded Himself With Sycophants - November 20th, 2022 [November 20th, 2022]
- Experts Baffled by Why NASA’s “Red Crew” Wear Blue Shirts - November 20th, 2022 [November 20th, 2022]
- NASA Drops Stunning New James Webb Image of a Star Being Born - November 20th, 2022 [November 20th, 2022]
- Ticketmaster May Have Finally Met Its Match: Furious Swifties - November 20th, 2022 [November 20th, 2022]
- Elon Musk Locks Twitter Employees Out Office, Then Asks Them to Meet Him on the 10th Floor - November 20th, 2022 [November 20th, 2022]
- NASA Tells Astronauts That Tweeting Isn't As Important as Staying Alive - November 20th, 2022 [November 20th, 2022]
- NASA Orders Press Not to Photograph Launch Site After Moon Mission Takes Off - November 20th, 2022 [November 20th, 2022]
- Amazing Map Lets You Scroll Through the Entire Known Universe - November 20th, 2022 [November 20th, 2022]
- Experts Excoriate NASA Report Claiming James Webb Wasn't Homophobic - November 20th, 2022 [November 20th, 2022]
- So Many People Are Using a Diabetes Drug for Weight Loss That Actual Diabetics Are Having Trouble Getting It - November 20th, 2022 [November 20th, 2022]
- Behind the Lawsuit Against Celebs Who Shilled FTX Before Its Spectacular Meltdown - November 20th, 2022 [November 20th, 2022]
- Twitter Claims Video of Moon Rocket Launch Is Revenge Porn - November 20th, 2022 [November 20th, 2022]
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022 [November 4th, 2022]
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022 [November 4th, 2022]
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022 [November 4th, 2022]
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022 [November 4th, 2022]
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022 [November 4th, 2022]
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022 [November 4th, 2022]
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022 [November 4th, 2022]
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022 [November 4th, 2022]
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022 [November 4th, 2022]
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022 [November 4th, 2022]
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022 [November 4th, 2022]
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022 [November 4th, 2022]
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022 [November 4th, 2022]
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022 [November 4th, 2022]
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022 [November 4th, 2022]
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022 [November 4th, 2022]
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022 [November 4th, 2022]
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022 [November 4th, 2022]
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022 [November 4th, 2022]
- Global Stem Cell Banking Market Research Report 2022: Market to Reach $11.5 Billion by 2026 - Adult Stem Cell Research Gains Traction, Accelerating... - October 27th, 2022 [October 27th, 2022]
- Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women... - July 8th, 2022 [July 8th, 2022]
- Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times - July 8th, 2022 [July 8th, 2022]
- Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL - Cancer Network - July 8th, 2022 [July 8th, 2022]
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022 [July 8th, 2022]
- Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire - July 8th, 2022 [July 8th, 2022]
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022 [July 8th, 2022]
- Global Lupus Market is Expected to Reach USD 4.3 Billion With CAGR of 12.41% By Forecast 2027 Says Maximize Market Research (MMR) - Digital Journal - July 8th, 2022 [July 8th, 2022]
- Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference - GuruFocus.com - July 8th, 2022 [July 8th, 2022]
- TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts - GuruFocus.com - July 8th, 2022 [July 8th, 2022]
- Global Adrenoleukodystrophy Treatment Market Trends, Growth, Opportunities and Forecast to 2029 Designer Women - Designer Women - July 8th, 2022 [July 8th, 2022]
- Mayo Clinic Q and A: Stem cell therapy for arthritis ... - November 29th, 2021 [November 29th, 2021]
- FDA Warns About Stem Cell Therapies | FDA - November 29th, 2021 [November 29th, 2021]
- A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - The New York Times - November 29th, 2021 [November 29th, 2021]
- Cell Therapy Markets, 2030 - ResearchAndMarkets.com - Business Wire - November 29th, 2021 [November 29th, 2021]
- Neuroplast secures 10 million in funding to boost clinical development of stem cell therapy for traumatic spinal cord injuries - Spinal News... - November 29th, 2021 [November 29th, 2021]
- Innovating Reversible Cell Therapies With RNA - Technology Networks - November 29th, 2021 [November 29th, 2021]
- US Stem Cell Therapy Market size and analysis by leading manufacturers, application and types 2021-2027 Energy Siren - Energy Siren - November 29th, 2021 [November 29th, 2021]
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - Galveston County Daily... - November 29th, 2021 [November 29th, 2021]
- Susanna Park inducted as holder of Roth Endowed Chair for Discovery, Education and Patient Care - UC Davis Health - November 29th, 2021 [November 29th, 2021]
- Covid vaccine: Stem cell transplant patients who must be completely re-vaccinated struggling to book jabs - iNews - November 29th, 2021 [November 29th, 2021]
- Immunomic Therapeutics Announces Collaboration With iOncologi - BioSpace - November 29th, 2021 [November 29th, 2021]
- An Against-the-Odds Cancer Story Can Be Yours - Curetoday.com - November 29th, 2021 [November 29th, 2021]
- Calls for stem cell donation to change in Australia to reduce reliance on overseas donors - ABC News - November 29th, 2021 [November 29th, 2021]
- The Expanding Role of Interferons in Myeloproliferative Neoplasms - Targeted Oncology - November 29th, 2021 [November 29th, 2021]
- Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma - OncLive - September 5th, 2021 [September 5th, 2021]
- Cell Therapy Manufacturing Market | Exclusive Report on the Latest Market Trends and Development - PharmiWeb.com - September 5th, 2021 [September 5th, 2021]
- MD Anderson Now to Offer Solution for Cellular Therapy Toxicities - Targeted Oncology - September 5th, 2021 [September 5th, 2021]
- NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network - September 5th, 2021 [September 5th, 2021]
- BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - GuruFocus.com - September 5th, 2021 [September 5th, 2021]
- Jury awards North Texas doctor $7.8 million in lawsuit over his partner locking him out - The Dallas Morning News - September 5th, 2021 [September 5th, 2021]
- Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML - Targeted Oncology - September 5th, 2021 [September 5th, 2021]
- Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas - OncLive - September 5th, 2021 [September 5th, 2021]
- MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe Safety Switch - Newswise - September 5th, 2021 [September 5th, 2021]
- Hematopoietic Stem Cell Transplantation (HSCT) Market by Sales, Revenue, Price and Gross Margin (2021-2027) UNLV The Rebel Yell - UNLV The Rebel Yell - September 5th, 2021 [September 5th, 2021]